• 1
    Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989; 141: 10761083.
  • 2
    Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992; 267: 22152220.
  • 3
    Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150: 110114.
  • 4
    Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993; 71: 20312040.
  • 5
    Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909916.
  • 6
    D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004; 351: 125135.
  • 7
    Stephenson AJ, Aprikian AG, Souhami L, et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology. 2002; 59: 652656.
  • 8
    D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003; 95: 13761383.
  • 9
    D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004; 172(5 Pt 2): S42S46; discussion, S46–S47.
  • 10
    Schmid HP, Semjonow A, Maibach R. Prostate-specific antigen doubling time: a potential surrogate end point in hormone-refractory prostate cancer. J Clin Oncol. 1999; 17: 16451646.
  • 11
    Pruthi RS, Johnstone I, Tu IP, Stamey TA. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology. 1997; 49: 737742.
  • 12
    Morrell CH, Pearson JD, Carter HB, Brant LJ. Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. J Am Stat Assoc. 1995; 90: 4553.
  • 13
    Leibman BD, Dillioglugil O, Scardino PT, et al. Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis. J Clin Oncol. 1998; 16: 22672271.
  • 14
    Rabbani F, Perrotti M, Bastar A, Fair WR. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy. J Urol. 1999; 161: 847852.
  • 15
    Soergel TM, Koch MO, Foster RS, et al. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol. 2001; 166: 21982201.
  • 16
    Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 34613467.
  • 17
    Diggle P, Heagerty P, Liang KY, Zeger S. Analysis of longitudinal data, 2nd ed. New York: Oxford University Press, 2002.
  • 18
    Slate EH, Turnbull, BW. Statistical models for longitudinal biomarkers of disease onset. Stat Med. 2000; 19: 617637.
  • 19
    Nagelkerke N. A note on a general definition of the coefficient of determination. Biometrika. 1991; 78: 691692.
  • 20
    Shulman MJ, Benaim EA. The natural history of androgen independent prostate cancer. J Urol. 2004; 172: 141145.
  • 21
    Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003; 170: 18721876.
  • 22
    Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI. Prostate-specific antigen as a marker of disease activity in prostate cancer [review]. Oncology (Williston Park). 2002; 16: 12181224; discussion, 1224, 1227–1228 passim.
  • 23
    Pauler DK, Finkelstein DM. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. Stat Med. 2002; 21: 38973911.
  • 24
    Cronin K, Slate EH, Turnbull, BW, Wells MT. Using the Gibbs sampler to detect changepoints: application to PSA as a longitudinal marker for prostate cancer. Comput Sci Stat. 1994; 26: 314318.
  • 25
    Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 15021512.
  • 26
    Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995; 46: 142148.
  • 27
    Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 15131520.